These findings suggest a molecular mechanism for the deregulated Bcl-2 expression observed in AIDS-KS lesions and confirm that Bcl-2 may represent a key target for therapeutic intervention of KS. This evidence concerns the gene BCL2 and Kaposi's sarcoma.